BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kallen AJ, Jhung MA, Cheng S, Hess T, Turabelidze G, Abramova L, Arduino M, Guarner J, Pollack B, Saab G, Patel PR. Gadolinium-containing magnetic resonance imaging contrast and nephrogenic systemic fibrosis: a case-control study. Am J Kidney Dis 2008;51:966-75. [PMID: 18501784 DOI: 10.1053/j.ajkd.2007.12.036] [Cited by in Crossref: 73] [Cited by in F6Publishing: 55] [Article Influence: 5.6] [Reference Citation Analysis]
Number Citing Articles
1 Penfield JG, Reilly RF. Gadolinium and Nephrogenic Systemic Fibrosis: Have We Overreacted?: GADOLINIUM AND NEPHROGENIC SYSTEMIC FIBROSIS. Seminars in Dialysis 2011;24:480-6. [DOI: 10.1111/j.1525-139x.2011.00945.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Stirrup J, Maenhout A, Wechalekar K, Anagnostopoulos C. Radionuclide imaging in ischaemic heart failure. Br Med Bull 2009;92:43-59. [PMID: 19710085 DOI: 10.1093/bmb/ldp029] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
3 van der Molen A. Nephrogenic systemic fibrosis and the role of gadolinium contrast media. Journal of Medical Imaging and Radiation Oncology 2008;52:339-50. [DOI: 10.1111/j.1440-1673.2008.01965.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
4 Prince MR, Zhang HL, Prowda JC, Grossman ME, Silvers DN. Nephrogenic Systemic Fibrosis and Its Impact on Abdominal Imaging. RadioGraphics 2009;29:1565-74. [DOI: 10.1148/rg.296095517] [Cited by in Crossref: 66] [Cited by in F6Publishing: 46] [Article Influence: 5.5] [Reference Citation Analysis]
5 Abujudeh HH, Kaewlai R, Kagan A, Chibnik LB, Nazarian RM, High WA, Kay J. Nephrogenic Systemic Fibrosis after Gadopentetate Dimeglumine Exposure: Case Series of 36 Patients. Radiology 2009;253:81-9. [DOI: 10.1148/radiol.2531082160] [Cited by in Crossref: 76] [Cited by in F6Publishing: 65] [Article Influence: 6.3] [Reference Citation Analysis]
6 Swaminathan S. Gadolinium toxicity: Iron and ferroportin as central targets. Magn Reson Imaging 2016;34:1373-6. [PMID: 27580520 DOI: 10.1016/j.mri.2016.08.016] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 6.0] [Reference Citation Analysis]
7 Weyker PD, Pérez XL, Liu KD. Management of Acute Kidney Injury and Acid-Base Balance in the Septic Patient. Clin Chest Med 2016;37:277-88. [PMID: 27229644 DOI: 10.1016/j.ccm.2016.01.012] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
8 Gerretsen SC, le Maire TF, Miller S, Thurnher SA, Herborn CU, Michaely HJ, Kramer H, Vanzulli A, Vymazal J, Wasser MN, Ballarati CE, Kirchin MA, Pirovano G, Leiner T. Multicenter, double-blind, randomized, intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine for MR angiography of peripheral arteries. Radiology 2010;255:988-1000. [PMID: 20501735 DOI: 10.1148/radiol.10090357] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 3.3] [Reference Citation Analysis]
9 Semelka RC, Ramalho M, Alobaidy M, Ramalho J. Gadolinium in Humans: A Family of Disorders. American Journal of Roentgenology 2016;207:229-33. [DOI: 10.2214/ajr.15.15842] [Cited by in Crossref: 62] [Cited by in F6Publishing: 16] [Article Influence: 12.4] [Reference Citation Analysis]
10 Andreucci M, Solomon R, Tasanarong A. Side effects of radiographic contrast media: pathogenesis, risk factors, and prevention. Biomed Res Int 2014;2014:741018. [PMID: 24895606 DOI: 10.1155/2014/741018] [Cited by in Crossref: 42] [Cited by in F6Publishing: 66] [Article Influence: 6.0] [Reference Citation Analysis]
11 Mihai G, Chung Y, Kariisa M, Raman SV, Simonetti OP, Rajagopalan S. Initial feasibility of a multi-station high resolution three-dimensional dark blood angiography protocol for the assessment of peripheral arterial disease. J Magn Reson Imaging 2009;30:785-93. [DOI: 10.1002/jmri.21923] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
12 Perazella MA. Advanced kidney disease, gadolinium and nephrogenic systemic fibrosis: the perfect storm. Curr Opin Nephrol Hypertens 2009;18:519-25. [PMID: 19623065 DOI: 10.1097/MNH.0b013e3283309660] [Cited by in Crossref: 34] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
13 Raczeck P, Fries P, Bücker A, Schneider G. [Gadolinium deposition-"gadolinium deposition disease"]. Radiologe 2019;59:435-43. [PMID: 30963195 DOI: 10.1007/s00117-019-0522-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
14 Zou Z, Zhang HL, Roditi GH, Leiner T, Kucharczyk W, Prince MR. Nephrogenic systemic fibrosis: review of 370 biopsy-confirmed cases. JACC Cardiovasc Imaging 2011;4:1206-16. [PMID: 22093272 DOI: 10.1016/j.jcmg.2011.08.013] [Cited by in Crossref: 70] [Cited by in F6Publishing: 56] [Article Influence: 7.8] [Reference Citation Analysis]
15 Kadiyala D, Roer DA, Perazella MA. Nephrogenic Systemic Fibrosis Associated With Gadoversetamide Exposure: Treatment With Sodium Thiosulfate. American Journal of Kidney Diseases 2009;53:133-7. [DOI: 10.1053/j.ajkd.2008.09.016] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 2.4] [Reference Citation Analysis]
16 Abdel-Kader K, Patel PR, Kallen AJ, Sinkowitz-Cochran RL, Bolton WK, Unruh ML. Nephrogenic systemic fibrosis: a survey of nephrologists' perceptions and practices. Clin J Am Soc Nephrol 2010;5:964-71. [PMID: 20299369 DOI: 10.2215/CJN.00140110] [Cited by in Crossref: 7] [Article Influence: 0.6] [Reference Citation Analysis]
17 Matsumoto Y, Mitsuhashi Y, Monma F, Kawaguchi M, Suzuki T, Miyabe C, Igarashi A, Tsuboi R. Nephrogenic systemic fibrosis: a case report and review on Japanese patients. J Dermatol 2012;39:449-53. [PMID: 22035371 DOI: 10.1111/j.1346-8138.2011.01407.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
18 Aryal S, Key J, Stigliano C, Ananta JS, Zhong M, Decuzzi P. Engineered magnetic hybrid nanoparticles with enhanced relaxivity for tumor imaging. Biomaterials 2013;34:7725-32. [PMID: 23871540 DOI: 10.1016/j.biomaterials.2013.07.003] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 5.4] [Reference Citation Analysis]
19 Perazella MA, Reilly RF. Imaging patients with kidney disease: how do we approach contrast-related toxicity? Am J Med Sci 2011;341:215-21. [PMID: 21139495 DOI: 10.1097/MAJ.0b013e3181f016e6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
20 Do C, Barnes JL, Tan C, Wagner B. Type of MRI contrast, tissue gadolinium, and fibrosis. Am J Physiol Renal Physiol 2014;307:F844-55. [PMID: 25100280 DOI: 10.1152/ajprenal.00379.2014] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 4.3] [Reference Citation Analysis]
21 Wiedemeyer K, Kutzner H, Abraham JL, Thakral C, Carlson JA, Tran TA, Hausser I, Hartschuh W. The Evolution of Osseous Metaplasia in Localized Cutaneous Nephrogenic Systemic Fibrosis: A Case Report. The American Journal of Dermatopathology 2009;31:674-81. [DOI: 10.1097/dad.0b013e3181a1fb55] [Cited by in Crossref: 14] [Cited by in F6Publishing: 2] [Article Influence: 1.2] [Reference Citation Analysis]
22 Lee VS. MRI: From science to society. J Magn Reson Imaging 2013;37:753-60. [DOI: 10.1002/jmri.24044] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
23 Bardin T, Richette P. Rheumatic manifestations of renal disease. Current Opinion in Rheumatology 2009;21:55-61. [DOI: 10.1097/bor.0b013e32831ca5c5] [Cited by in Crossref: 4] [Article Influence: 0.3] [Reference Citation Analysis]
24 Mazhar SM, Shiehmorteza M, Kohl CA, Middleton MS, Sirlin CB. Nephrogenic systemic fibrosis in liver disease: a systematic review. J Magn Reson Imaging 2009;30:1313-22. [PMID: 19937937 DOI: 10.1002/jmri.21983] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
25 Bak SH, Roh HG, Moon WJ, Choi JW, An HS. Appropriate Minimal Dose of Gadobutrol for 3D Time-Resolved MRA of the Supra-Aortic Arteries: Comparison with Conventional Single-Phase High-Resolution 3D Contrast-Enhanced MRA. AJNR Am J Neuroradiol 2017;38:1383-90. [PMID: 28473338 DOI: 10.3174/ajnr.A5176] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
26 Bruce R, Wentland AL, Haemel AK, Garrett RW, Sadowski DR, Djamali A, Sadowski EA. Incidence of Nephrogenic Systemic Fibrosis Using Gadobenate Dimeglumine in 1423 Patients With Renal Insufficiency Compared With Gadodiamide. Invest Radiol. 2016;51:701-705. [PMID: 26885631 DOI: 10.1097/rli.0000000000000259] [Cited by in Crossref: 34] [Cited by in F6Publishing: 16] [Article Influence: 8.5] [Reference Citation Analysis]
27 Kitajima K, Maeda T, Watanabe S, Ueno Y, Sugimura K. Recent topics related to nephrogenic systemic fibrosis associated with gadolinium-based contrast agents. Int J Urol 2012;19:806-11. [PMID: 22571387 DOI: 10.1111/j.1442-2042.2012.03042.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
28 Alhadad A, Sterner G, Svensson Å, Alhadad H, Leander P. Incidence of nephrogenic systemic fibrosis at a large university hospital in Sweden. Scandinavian Journal of Urology and Nephrology 2012;46:48-53. [DOI: 10.3109/00365599.2011.621142] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
29 Zou Z, Ma L. Nephrogenic systemic fibrosis: review of 408 biopsy-confirmed cases. Indian J Dermatol. 2011;56:65-73. [PMID: 21572796 DOI: 10.4103/0019-5154.77556] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
30 Galea N, Francone M, Zaccagna F, Ciolina F, Cannata D, Algeri E, Agati L, Catalano C, Carbone I. Ultra low-dose of gadobenate dimeglumine for late gadolinium enhancement (LGE) imaging in acute myocardial infarction: A feasibility study. European Journal of Radiology 2014;83:2151-8. [DOI: 10.1016/j.ejrad.2014.09.002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
31 Ebrahimi B, Textor SC, Lerman LO. Renal relevant radiology: renal functional magnetic resonance imaging. Clin J Am Soc Nephrol 2014;9:395-405. [PMID: 24370767 DOI: 10.2215/CJN.02900313] [Cited by in Crossref: 48] [Cited by in F6Publishing: 24] [Article Influence: 6.0] [Reference Citation Analysis]
32 Takahashi EA, Kallmes DF, Mara KC, Harmsen WS, Misra S. Nephrotoxicity of gadolinium-based contrast in the setting of renal artery intervention: retrospective analysis with 10-year follow-up. Diagn Interv Radiol 2018;24:378-84. [PMID: 30406762 DOI: 10.5152/dir.2018.18172] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
33 Reiter T, Ritter O, Prince MR, Nordbeck P, Wanner C, Nagel E, Bauer WR. Minimizing risk of nephrogenic systemic fibrosis in cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2012;14:31. [PMID: 22607376 DOI: 10.1186/1532-429X-14-31] [Cited by in Crossref: 62] [Cited by in F6Publishing: 25] [Article Influence: 6.9] [Reference Citation Analysis]
34 Vlijm A, van Schuppen J, Lamers AB, Struijk DG, Krediet RT. Imaging in encapsulating peritoneal sclerosis. NDT Plus 2011;4:281-4. [PMID: 25984169 DOI: 10.1093/ndtplus/sfr068] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
35 Wagner B, Drel V, Gorin Y. Pathophysiology of gadolinium-associated systemic fibrosis. Am J Physiol Renal Physiol 2016;311:F1-F11. [PMID: 27147669 DOI: 10.1152/ajprenal.00166.2016] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 6.2] [Reference Citation Analysis]
36 Leiner T, Kucharczyk W. Special issue: nephrogenic systemic fibrosis. J Magn Reson Imaging 2009;30:1233-5. [PMID: 19938034 DOI: 10.1002/jmri.21985] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
37 Martin DR, Semelka RC, Chapman A, Peters H, Finn PJ, Kalb B, Thomsen H. Nephrogenic systemic fibrosis versus contrast-induced nephropathy: Risks and benefits of contrast-enhanced MR and CT in renally impaired patients. J Magn Reson Imaging 2009;30:1350-6. [DOI: 10.1002/jmri.21968] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 3.0] [Reference Citation Analysis]
38 Choi JA, Gold GE. MR imaging of articular cartilage physiology. Magn Reson Imaging Clin N Am 2011;19:249-82. [PMID: 21665090 DOI: 10.1016/j.mric.2011.02.010] [Cited by in Crossref: 80] [Cited by in F6Publishing: 73] [Article Influence: 8.0] [Reference Citation Analysis]
39 Zhang B, Liang L, Chen W, Liang C, Zhang S. An Updated Study to Determine Association between Gadolinium-Based Contrast Agents and Nephrogenic Systemic Fibrosis. PLoS One 2015;10:e0129720. [PMID: 26076348 DOI: 10.1371/journal.pone.0129720] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
40 Daftari Besheli L, Aran S, Shaqdan K, Kay J, Abujudeh H. Current status of nephrogenic systemic fibrosis. Clin Radiol. 2014;69:661-668. [PMID: 24582176 DOI: 10.1016/j.crad.2014.01.003] [Cited by in Crossref: 78] [Cited by in F6Publishing: 56] [Article Influence: 11.1] [Reference Citation Analysis]
41 Attari H, Cao Y, Elmholdt TR, Zhao Y, Prince MR. A Systematic Review of 639 Patients with Biopsy-confirmed Nephrogenic Systemic Fibrosis. Radiology. 2019;292:376-386. [PMID: 31264946 DOI: 10.1148/radiol.2019182916] [Cited by in Crossref: 43] [Cited by in F6Publishing: 35] [Article Influence: 21.5] [Reference Citation Analysis]
42 Perazella MA. Magnetic resonance imaging in ESRD patients: what are the options? Semin Dial 2014;27:610-3. [PMID: 25039646 DOI: 10.1111/sdi.12271] [Reference Citation Analysis]
43 Weller A, Barber JL, Olsen ØE. Gadolinium and nephrogenic systemic fibrosis: an update. Pediatr Nephrol 2014;29:1927-37. [DOI: 10.1007/s00467-013-2636-z] [Cited by in Crossref: 51] [Cited by in F6Publishing: 43] [Article Influence: 6.4] [Reference Citation Analysis]
44 Duijm LEM, Overbosch EH, Liem YS, Planken RN, Tordoir JHM, Cuypers PWM, Douwes-draaijer P, de Haan MW. Retrograde catheterization of haemodialysis fistulae and grafts: angiographic depiction of the entire vascular access tree and stenosis treatment. Nephrology Dialysis Transplantation 2008;24:539-47. [DOI: 10.1093/ndt/gfn526] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
45 Braun HJ, Gold GE. Advanced MRI of articular cartilage.Imaging Med. 2011;3:541-555. [PMID: 22162977 DOI: 10.2217/iim.11.43] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
46 Anzidei M, Napoli A, Zaccagna F, Cavallo Marincola B, Zini C, Kirchin MA, Catalano C, Passariello R. First-Pass and High-Resolution Steady-State Magnetic Resonance Angiography of the Peripheral Arteries With Gadobenate Dimeglumine: An Assessment of Feasibility and Diagnostic Performance. Investigative Radiology 2011;46:307-16. [DOI: 10.1097/rli.0b013e3182021879] [Cited by in Crossref: 13] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
47 Provenzale JM. Nephrogenic Systemic Fibrosis: Some Considerations on the Debate Regarding Its Cause. American Journal of Roentgenology 2008;191:1867-9. [DOI: 10.2214/ajr.08.1541] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
48 Knapp BA, Sepahpanah F. Nephrogenic Systemic Fibrosis in a Patient With Spinal Cord Injury: A Unique Case Presentation. PM&R 2010;2:1141-4. [DOI: 10.1016/j.pmrj.2010.07.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
49 Gitsioudis G, Stuber M, Arend I, Thomas M, Yu J, Hilbel T, Giannitsis E, Katus HA, Korosoglou G. Steady-state equilibrium phase inversion recovery ON-resonant water suppression (IRON) MR angiography in conjunction with superparamagnetic nanoparticles. A robust technique for imaging within a wide range of contrast agent dosages. J Magn Reson Imaging 2013;38:836-44. [PMID: 23418107 DOI: 10.1002/jmri.24043] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
50 Kirchin MA, Lorusso V, Pirovano G. Compensatory biliary and urinary excretion of gadobenate ion after administration of gadobenate dimeglumine (MultiHance(®)) in cases of impaired hepatic or renal function: a mechanism that may aid in the prevention of nephrogenic systemic fibrosis? Br J Radiol 2015;88:20140526. [PMID: 25651409 DOI: 10.1259/bjr.20140526] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
51 Soyer P, Dohan A, Patkar D, Gottschalk A. Observational study on the safety profile of gadoterate meglumine in 35,499 patients: The SECURE study. J Magn Reson Imaging. 2017;45:988-997. [PMID: 27726239 DOI: 10.1002/jmri.25486] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 6.8] [Reference Citation Analysis]
52 Chopra T, Kandukurti K, Shah S, Ahmed R, Panesar M. Understanding nephrogenic systemic fibrosis. Int J Nephrol. 2012;2012:912189. [PMID: 23193473 DOI: 10.1155/2012/912189] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
53 Prince MR, Zhang HL, Roditi GH, Leiner T, Kucharczyk W. Risk factors for NSF: a literature review. J Magn Reson Imaging. 2009;30:1298-1308. [PMID: 19937930 DOI: 10.1002/jmri.21973] [Cited by in Crossref: 94] [Cited by in F6Publishing: 77] [Article Influence: 8.5] [Reference Citation Analysis]
54 Blankholm AD, Ringgaard S. Non-contrast-enhanced magnetic resonance angiography: techniques and applications. Expert Review of Cardiovascular Therapy 2014;10:75-88. [DOI: 10.1586/erc.11.176] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
55 Zou Z, Ma L, Li H. Incidence of nephrogenic systemic fibrosis at Chinese PLA General Hospital. J Magn Reson Imaging 2009;30:1309-12. [DOI: 10.1002/jmri.21769] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]